Zahra Nazari Taloki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zahra Nazari Taloki has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ali Talebi
Department of Clinical Pharmacy Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran
1 shared publication - Alia Shakiba
Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication Atieh Makhlough
Department of Nephrology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publicationEbrahim Salehifar
Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication- Marjan Moghadamnia
Department of Pharmacotherapy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
1 shared publication - Niayesh Mohebbi
Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 26 August 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Could Alpha-Lipoic Acid Improve Arteriovenous Fistula Maturation? A Mechanistic Hypothesis
Could Alpha-Lipoic Acid Improve Arteriovenous Fistula Maturation? A Mechanistic Hypothesis
- 26 August 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Could Alpha-Lipoic Acid Improve Arteriovenous Fistula Maturation? A Mechanistic Hypothesis
Could Alpha-Lipoic Acid Improve Arteriovenous Fistula Maturation? A Mechanistic Hypothesis
- Open Access
- 25 May 2026
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 16 (1) , 33590
Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential
Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential
- 25 May 2026
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 16 (1) , 33590
Open AccessLevosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential
Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential
- Open Access
- 25 May 2026
- Vol. 16, 33590
Levosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential
- 25 May 2026
- Vol. 16, 33590
Open AccessLevosimendan in burn wound ischemia: Mechanistic rationale and therapeutic potential
- Open Access
- 21 January 2026
- Vol. 17 (1) , 211-212
Sodium-glucose transport 2 inhibitors: Practical management of the venetoclax-induced adverse events
- 21 January 2026
- Vol. 17 (1) , 211-212
Open AccessSodium-glucose transport 2 inhibitors: Practical management of the venetoclax-induced adverse events
- Open Access
- 22 November 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15
Spirulina: A promising opportunity to overcome neuropathic pain challenges in chronic kidney disease patients
- 22 November 2025
- Published by Maad Rayan Publishing Company in BioImpacts
- Vol. 15
Open AccessSpirulina: A promising opportunity to overcome neuropathic pain challenges in chronic kidney disease patients
- Open Access
- 8 August 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (158) , 246-248
Eltrombopag in Wound Healing Pharmacotherapy! An Artistic Repurposing?
Highlights: 1. The valuable role of platelets and their derivatives in regenerative medicine cannot be overstated, with benefits including increased collagen formation, bacteriostatic effects, and reduced inflammation. 2. The promising therapeutic effects of iron chelating agents, including stimulation of angiogenesis and reduction of oxidative stress, are consistent with the multiple ...
- 8 August 2025
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 33 (158) , 246-248
Open AccessEltrombopag in Wound Healing Pharmacotherapy! An Artistic Repurposing?
Highlights: 1. The valuable role of platelets and their derivatives in regenerative medicine cannot be overstated, with benefits including increased collagen formation, bacteriostatic effects, and reduced inflammation. 2. The promising therapeutic effects of iron chelating agents, including stimulation of angiogenesis and reduction of oxidative stress, are consistent with the multiple ...
- 2 December 2024
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 29 (6) , 533
Agomelatine: The Cinderella of migraine pharmacotherapy in pediatrics?
- 2 December 2024
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 29 (6) , 533
Agomelatine: The Cinderella of migraine pharmacotherapy in pediatrics?
- 3 August 2023
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 29 (4) , 495-503
Effect of Recommended Dietary Intake versus Higher Doses of Supplemental Zinc on Iron and Copper Deficiency Anemia Among Patients with Chronic Kidney Diseases, A Double-Blinded, Randomized Clinical Trial
Background: Complex interplays happen in absorption and function of iron, zinc and copper. Both zinc deficiency and excess may lead to anemia. In Iran, commonly available supplements for chronic kidney disease (CKD) patients contain 25 mg-zinc (Zn). This study compared 25 mg versus 7.5 mg dose of zinc in anemia of CKD patients, the latter dose approximates to recommended dietary intake (RDI) of zinc. Methods: In this double-blinded clinical trial, 51 non-dialysis CKD patients were randomized to continue previous formulation (25 mg-Zn group) or change to a new preparation (7.5 mg-Zn group) for three months. Blood counts and serum iron, zinc and copper status were compared between and within the groups. Results: At the end of the study, serum copper and ceruloplasmin concentrations were significantly higher in 7.5 mg-Zn group compared with those in 25 mg-Zn arm (115.04± 23.05 vs. 102.48±14.98 µg/dL; P= 0.02 and 29.97±7.94 vs. 25.42±4.23 mg/dL; P= 0.01, respectively). Serum zinc levels did not differ between two groups (76.73±15.35 vs. 77.68±18.07 µg/dL for 7.5 mg-Zn and 25 mg-Zn groups, respectively; P= 0.84). After three months, patients in 7.5 mg-Zn group experienced increase in their Hb (11.11±1.17 vs. 10.72±1.03 g/dL; P= 0.04), HCT (35.28± 4.01 vs. 33.96± 3.74%; P= 0.03), MCV (86.30 (81.40-90.82) vs. 86.00 (80.35-88.77) ¦L; P= 0.01) and ferritin (202.60 (79.29-298.97) vs. 129.07 (42.25-225.87) ng/mL; P<0.001) compared to their baseline values. Conclusion: Reducing zinc content to its RDI value in supplement for CKD patients led to increased serum copper and ceruloplasmin concentrations. Moreover, patients who switched to RDI zinc-containing formula experienced a significant rise in blood hemoglobin. hematocrit, mean corpuscular volume (MCV), and ferritin concentration.
- 3 August 2023
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 29 (4) , 495-503
Effect of Recommended Dietary Intake versus Higher Doses of Supplemental Zinc on Iron and Copper Deficiency Anemia Among Patients with Chronic Kidney Diseases, A Double-Blinded, Randomized Clinical Trial
Background: Complex interplays happen in absorption and function of iron, zinc and copper. Both zinc deficiency and excess may lead to anemia. In Iran, commonly available supplements for chronic kidney disease (CKD) patients contain 25 mg-zinc (Zn). This study compared 25 mg versus 7.5 mg dose of zinc in anemia of CKD patients, the latter dose approximates to recommended dietary intake (RDI) of zinc. Methods: In this double-blinded clinical trial, 51 non-dialysis CKD patients were randomized to continue previous formulation (25 mg-Zn group) or change to a new preparation (7.5 mg-Zn group) for three months. Blood counts and serum iron, zinc and copper status were compared between and within the groups. Results: At the end of the study, serum copper and ceruloplasmin concentrations were significantly higher in 7.5 mg-Zn group compared with those in 25 mg-Zn arm (115.04± 23.05 vs. 102.48±14.98 µg/dL; P= 0.02 and 29.97±7.94 vs. 25.42±4.23 mg/dL; P= 0.01, respectively). Serum zinc levels did not differ between two groups (76.73±15.35 vs. 77.68±18.07 µg/dL for 7.5 mg-Zn and 25 mg-Zn groups, respectively; P= 0.84). After three months, patients in 7.5 mg-Zn group experienced increase in their Hb (11.11±1.17 vs. 10.72±1.03 g/dL; P= 0.04), HCT (35.28± 4.01 vs. 33.96± 3.74%; P= 0.03), MCV (86.30 (81.40-90.82) vs. 86.00 (80.35-88.77) ¦L; P= 0.01) and ferritin (202.60 (79.29-298.97) vs. 129.07 (42.25-225.87) ng/mL; P<0.001) compared to their baseline values. Conclusion: Reducing zinc content to its RDI value in supplement for CKD patients led to increased serum copper and ceruloplasmin concentrations. Moreover, patients who switched to RDI zinc-containing formula experienced a significant rise in blood hemoglobin. hematocrit, mean corpuscular volume (MCV), and ferritin concentration.
- Open Access
- 30 May 2020
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 11 (2) , 147-162
Drug Interactions of Psychiatric and COVID-19 Medications
Introduction: Coronavirus disease 2019 (COVID-19) has become a pandemic with 1771514 cases identified in the world and 70029 cases in Iran until April 12, 2020. The co-prescription of psychotropics with COVID-19 medication is not uncommon. Healthcare providers should be familiar with many Potential Drug-Drug Interactions (DDIs) between COVID-19 therapeutic agents and ...
- 30 May 2020
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 11 (2) , 147-162
Open AccessDrug Interactions of Psychiatric and COVID-19 Medications
Introduction: Coronavirus disease 2019 (COVID-19) has become a pandemic with 1771514 cases identified in the world and 70029 cases in Iran until April 12, 2020. The co-prescription of psychotropics with COVID-19 medication is not uncommon. Healthcare providers should be familiar with many Potential Drug-Drug Interactions (DDIs) between COVID-19 therapeutic agents and ...